Rett syndrome is a neurodevelopmental disorder mainly caused by de novo mutations in the MECP2 (methyl-CpG-binding protein 2) gene. There is considerable variation in the severity of clinical features among Rett syndrome patients, even among patients with the same MECP2 mutation. In addition to X-chromosome inactivation pattern, the genetic background of the affected individual might also have a role in determining the severity of the disorder. We suggest that APOE is one of the genetic modulating factors. We analyzed clinical phenotypes of 46 patients with Rett syndrome, with confirmed MECP2 mutation. We discovered that among ε4 carriers, some clinical features were more severe, and the developmental regression occurred 4 months earlier on average than in those without the ε4 allele. Earlier onset of regression suggests a possible trend; however, it did not achieve distinctive statistical significance. Nevertheless, the ε4 allele of APOE may serve as a candidate modulation factor for the Rett syndrome phenotype.
Armstrong DDReview of Rett syndrome. J Neuropathol Exp Neurol.1997;56(8):843-849.
2.
Laurvick CL, de Klerk N., Bower C., et al. Rett syndrome in Australia: a review of the epidemiology. J Pediatr. 2006;148(3):347-352.
3.
Percy AKRett syndrome: recent research progress. J Child Neurol. 2008;23(5):543-549.
4.
Naidu S.Rett syndrome: natural history and underlying disease mechanisms. Eur Child Adolesc Psychiatry. 1997;6(suppl 1): 14-17.
5.
Hagberg B., Aicardi J., Dias K., Ramos O.A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol. 1983; 14(4):471-479.
6.
Amir RE, Van den Veyver IB, Wan M., et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methylCpG-binding protein 2. Nat Genet. 1999 ;23(2):185-188.
7.
Bebbington A. , Anderson A., Ravine D., et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology . 2008;70(11):868-875.
8.
Neul JL, Fang P., Barrish J., et al. Specific mutations in methylCpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008 ;70(16):1313-1321.
9.
Ham AL, Kumar A., Deeter R., Schanen NCDoes genotype predict phenotype in Rett syndrome? J Child Neurol. 2005;20(9): 768-778.
10.
Scala E., Longo I., Ottimo F., et al. MECP2 deletions and genotype-phenotype correlation in Rett syndrome . Am J Med Genet A. 2007;143A(23):2775-2784.
11.
Ishii T., Makita Y., Ogawa A., et al. The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome. Brain Dev. 2001;23(suppl 1):S161-S164.
12.
Boyles JK, Zoellner CD, Anderson LJ, et al. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest. 1989 ;83(3): 1015-1031.
13.
Graham DI, Horsburgh K., Nicoll JA, Teasdale GMApolipoprotein E and the response of the brain to injury. Acta Neurochir Suppl. 1999;73:89-92.
14.
Poirier J., Baccichet A., Dea D., Gauthier S.Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience. 1993;55(1):81-90.
15.
Roses ADApolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387-400.
16.
Smith JDApolipoprotein E.4: an allele associated with many diseases. Ann Med. 2000;32(2):118-127.
17.
Del Bo R., Comi GP, Bresolin N., et al. The apolipoprotein E epsilon4 allele causes a faster decline of cognitive performances in Down’s syndrome subjects. J Neurol Sci. 1997;145(1):87-91.
18.
Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180-184.
19.
Schiefermeier M., Kollegger H., Madl C., et al. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson’s disease . Brain. 2000;123(pt 3): 585-590.
20.
Zahorakova D., Rosipal R., Hadac J., et al. Mutation analysis of the MECP2 gene in patients of Slavic origin with Rett syndrome: novel mutations and polymorphisms . J Hum Genet. 2007;52(4):342-348.
21.
Monros E., Armstrong J., Aibar E., et al. Rett syndrome in Spain: mutation analysis and clinical correlations . Brain Dev. 2001; 23(suppl 1):S251-S253.
22.
Hixson JE, Vernier DTRestriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545-548.
23.
Menzel HJ, Kladetzky RG, Assmann G.Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis. 1983; 3(4):310-315.
24.
Wan M., Lee SS, Zhang X., et al. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet. 1999;65(6):1520-1529.
25.
Villard L., Levy N., Xiang F., et al. Segregation of a totally skewed pattern of X chromosome inactivation in four familial cases of Rett syndrome without MECP2 mutation: implications for the disease. J Med Genet. 2001;38(7):435-442.
26.
Amir RE, Van den Veyver IB, Schultz R., et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol. 2000 ;47(5):670-679.
27.
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science . 1993;261(5123):921-923.
28.
Briellmann RS, Torn-Broers Y., Busuttil BE, et al. APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy. Neurology. 2000;55(3):435-437.
29.
Saunders AM , Strittmatter WJ, Schmechel D., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease . Neurology. 1993;43(8):1467-1472.
30.
Prasher VP, Chowdhury TA, Rowe BR, Bain SCApoE genotype and Alzheimer’s disease in adults with Down syndrome: meta-analysis. Am J Ment Retard. 1997;102(2):103-110.
31.
Lai F., Kammann E., Rebeck GW, Anderson A., Chen Y., Nixon RAAPOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology. 1999;53(2): 331-336.
32.
Mahley RW, Huang Y.Apolipoprotein E.: from atherosclerosis to Alzheimer’s disease and beyond. Curr Opin Lipidol. 1999;10(3): 207-217.
33.
Mahley RW, Weisgraber KH, Huang Y.Apolipoprotein E.4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006;103(15): 5644-5651.
34.
Mauch DH, Nagler K., Schumacher S., et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294(5545): 1354-1357.
35.
Ji Y., Gong Y., Gan W., Beach T., Holtzman DM, Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer’s disease patients. Neuroscience. 2003;122(2):305-315.
36.
Belichenko PV, Oldfors A., Hagberg B., Dahlstrom A.Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport. 1994;5(12):1509-1513.
37.
Fukuda T., Itoh M., Ichikawa T., Washiyama K., Goto Y.Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol. 2005;64(6):537-544.
